Vera Therapeutics (VERA) Share-based Compensation (2020 - 2026)

Vera Therapeutics (VERA) has 7 years of Share-based Compensation data on file, last reported at $13.2 million in Q1 2026.

• Quarterly Share-based Compensation rose 70.56% year-over-year to $13.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $43.4 million (up 77.67% YoY) and the FY2025 annual result came in at $66.0 million, up 33.87% from the prior year.
• Share-based Compensation grew to $13.2 million in Q1 2026, from $11.0 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $13.2 million in Q1 2026 to a low of -$4.1 million in Q4 2022.
• A 5-year average of $5.0 million and a median of $4.1 million in 2024 frame the typical range for Share-based Compensation.
• The widest YoY moves for Share-based Compensation: up 311.39% in 2022, down 530.25% in 2022.
• Tracing VERA's Share-based Compensation over 5 years: stood at -$4.1 million in 2022, then jumped by 177.82% to $3.2 million in 2023, then jumped by 93.01% to $6.2 million in 2024, then jumped by 76.37% to $11.0 million in 2025, then advanced by 20.46% to $13.2 million in 2026.
• The last three Share-based Compensation figures came in at $13.2 million (Q1 2026), $11.0 million (Q4 2025), and $9.7 million (Q3 2025), per Business Quant data.